Koźluk Edward, Piątkowska Agnieszka, Rodkiewicz Dariusz, Peller Michał, Kochanowski Janusz, Opolski Grzegorz
1 Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Department of Emergency Medicine, Wroclaw Medical University, Wroclaw, Poland.
Arch Med Sci. 2019 Jan;15(1):78-85. doi: 10.5114/aoms.2017.68054. Epub 2017 May 30.
Our aim was to compare in a prospective randomized study the safety, direct results and periprocedural data of ablation using an nMARQ catheter, a PVAC catheter used with the EnSite system, or a PVAC catheter only under fluoroscopy control.
One hundred two patients (70 male, 57 ±11 years) with atrial fibrillation (AF) were prospectively randomized to: group 1 - ablation performed with an nMARQ catheter and the CARTO 3 system; group 2 - a PVAC catheter used with the EnSite system; group 3 - ablation with a PVAC catheter without a 3D system.
Complete isolation of 400/402 pulmonary veins (PV) (99.5%). Linear ablation was performed in 23 patients in group 1 (small distance between lines isolating PV), in 3 patients in group 2, in 1 patient in group 3. The superior vena cava was isolated in 1 patient, 9 patients, and 9 patients respectively. Duration of fluoroscopy and dose area product were significantly smaller in group 1 (6.5 ±2.9 min/808.8 ±393.9 cGy/cm vs. 13.6 ±5.6 min/1662.6 ±677.8 cGy/cm and 18.8 ±7.6 min/2327.9 ±975.5 cGy/cm; < 0.001). Procedure duration was shorter in group 1 (82.9 ±18.8 min vs. 101.2 ±19.6 min, < 0.001 and 99.8 ±20.8 min, NS). Contrast injection was necessary in 2 patients in group 1, in 8 patients in group 2 and in all patients in group 3. Because nMARQ is a thermocool catheter, the volume of fluid injection was significantly greater (2348.5 ±543.5 ml vs. 1077.9 ±280.5 ml and 1076.5 ±375.6 ml, < 0.001). There were no periprocedural deaths. We observed no cardiac tamponade, neurological complications and no atrioesophageal fistula during follow-up.
The lowest radiological exposure was observed during ablation performed with an nMARQ catheter. 3D systems reduced fluoroscopy duration and the necessity of contrast injection. The nMARQ catheter requires injection of a large volume of fluid.
我们的目的是在一项前瞻性随机研究中比较使用nMARQ导管、与EnSite系统联用的PVAC导管或仅在透视控制下使用PVAC导管进行消融的安全性、直接结果和围手术期数据。
102例房颤(AF)患者(70例男性,年龄57±11岁)被前瞻性随机分为:第1组——使用nMARQ导管和CARTO 3系统进行消融;第2组——与EnSite系统联用的PVAC导管;第3组——不使用三维系统的PVAC导管进行消融。
402条肺静脉(PV)中的400条实现完全隔离(99.5%)。第1组23例患者进行了线性消融(隔离PV的线之间距离小),第2组3例,第3组1例。上腔静脉隔离分别为1例、9例和9例。第1组的透视时间和剂量面积乘积显著更小(6.5±2.9分钟/808.8±393.9 cGy/cm,对比13.6±5.6分钟/1662.6±677.8 cGy/cm和18.8±7.6分钟/2327.9±975.5 cGy/cm;P<0.001)。第1组的手术时间更短(82.9±18.8分钟,对比101.2±19.6分钟,P<0.001和99.8±20.8分钟,无显著性差异)。第1组2例患者需要注射造影剂,第2组8例,第3组所有患者均需要。由于nMARQ是一种热冷却导管,液体注射量显著更大(2348.5±543.5毫升,对比1077.9±280.5毫升和1076.5±375.6毫升,P<0.001)。围手术期无死亡病例。随访期间未观察到心脏压塞、神经并发症和房室食管瘘。
使用nMARQ导管进行消融时,放射暴露最低。三维系统减少了透视时间和造影剂注射的必要性。nMARQ导管需要注射大量液体。